New proprietary assembly technology pairs with groundbreaking complex DNA synthesis platform to deliver sequence-perfect clonal DNA as long as 5 kb
EMERYVILLE, Calif.--(BUSINESS WIRE)--#ClonalDNA--Ansa Biotechnologies, Inc., the trusted partner for complex DNA synthesis, today announced that it can now deliver its Ansa Clonal DNA product in lengths up to 5 kb. The longer constructs are made possible due to a new proprietary, sequence-agnostic assembly technology that was recently validated and released into production. Combining its complex DNA synthesis platform with a unique long-read sequencing and analysis approach for quality control allows Ansa to produce long, complex DNA more accurately and reliably than any other DNA synthesis vendor.
Ansa’s innovative platform enables direct synthesis of complex DNA sequences that other vendors are unable to produce. Its core synthesis technology produces contiguous sequences as long as 600 bases without the complexity limitations inherent to chemical DNA synthesis and other enzymatic DNA synthesis techniques. These 600-mers can serve as excellent building blocks for assembling longer sequences. However, all conventional assembly techniques feature some type of sequence constraint that makes them incompatible with certain DNA elements, preventing construction of the full range of sequences needed to advance biological engineering and the development of new therapeutics and sustainable products.
To overcome this challenge, Ansa’s R&D team developed a proprietary, sequence-agnostic assembly technology. Now, the process has been validated and implemented in Ansa’s DNA production facility, allowing Ansa to serve customers looking for DNA as long as 5 kb — even if those sequences include highly complex features such as repeats, hairpins, strong secondary structures, high GC content, and homopolymers. Once DNA has been synthesized and assembled, its sequence is verified using a highly accurate long-read sequencing technology paired with a unique informatics and analysis pipeline to ensure customers receive the exact DNA product they expect.
“Ansa was founded by synthetic biologists who deeply understood the frustrations associated with ordering — but often not receiving — the complex DNA they needed to enable important experiments,” said Jason T. Gammack, CEO of Ansa Biotechnologies. “Our entire production process has been developed around the goal of delivering a fresh experience for customers who need complex synthetic DNA and are sick of having their orders rejected, delayed, or unfulfilled by traditional vendors. At Ansa, we are committed to delivering complete orders, on time, with industry-leading accuracy and reliability so our customers can achieve scientific breakthroughs in biological engineering, novel therapies, and sustainable solutions.”
“Prior to working with Ansa, we had experienced several complex DNA sequence failures from an established vendor,” said Bo Jing, Vice President of Genome Design at Replay, a genome writing company. “Ansa provided the exact sequence we needed on the first attempt. We are able to work together to achieve our goals and complete projects that would have been impossible otherwise.”
Ansa’s enzymatic approach eliminates the need for harsh chemicals and does not damage the molecule as it is synthesized, enabling the direct synthesis of much longer strands than is possible with legacy chemical DNA synthesis techniques. Manufactured entirely in the USA, the Ansa products are easy to use and integrate into experimental workflows.
Live Webinar
At Stanford University, scientists in the Gao laboratory have used Ansa DNA products to support their unique approach to engineering protein secretion systems. This work involves sequence designs that often require complex cloning strategies, including minimal sequences and repetitive motifs, that have been too challenging for other vendors to produce. With reliable access to complex DNA, researchers can tune protein capabilities as easily as genetic circuits, with potential applications in cancer biology, immunology, and neuroscience. Scientists from Ansa and Dr. Gao’s lab will discuss this project during an upcoming webinar hosted by Fierce Biotech.
The Impact of Enzymatic DNA Synthesis on Compact Protein Circuitry for Regulating Protein Secretion Across Multiple Levels of the Central Dogma | ||||||||||
| Presenters: Connor Clayton Call, Stanford University, and Dan-Lin Arlow, Ansa Biotechnologies | |||||||||
| Date and time: December 10, 2024, 12:00 pm ET | |||||||||
| ||||||||||
For more information on Ansa Clonal DNA products, please visit ansabio.com/products.
About Ansa Biotechnologies
Ansa Biotechnologies is enabling customers to push the limits of their scientific projects by delivering DNA sequences that can be difficult or even impossible to produce with legacy synthesis techniques. Ansa’s unique services feature the company’s proprietary synthesis technology, which enables ultra-rapid enzymatic production of complex DNA sequences. This novel approach is poised to accelerate innovation across healthcare, life science research, and other industries powered by synthetic DNA. Ansa is headquartered in Emeryville, CA. For more information, visit ansabio.com or follow on X and LinkedIn.
Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.
Contacts
Media Contact
Andrew Noble
(415) 722-2129
andrew@bioscribe.com
